Shenzhen - Delayed Quote CNY

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ)

3.6900 -0.0400 (-1.07%)
At close: April 26 at 3:04 PM GMT+8
Key Events
Loading Chart for 300026.SZ
DELL
  • Previous Close 3.7300
  • Open 3.6600
  • Bid 3.6800 x --
  • Ask 3.6900 x --
  • Day's Range 3.5900 - 3.6900
  • 52 Week Range 3.0700 - 6.5900
  • Volume 39,553,868
  • Avg. Volume 40,955,967
  • Market Cap (intraday) 11.085B
  • Beta (5Y Monthly) -0.10
  • PE Ratio (TTM) 28.38
  • EPS (TTM) 0.1300
  • Earnings Date --
  • Forward Dividend & Yield 0.03 (0.81%)
  • Ex-Dividend Date May 12, 2023
  • 1y Target Est --

Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research, development, production, and marketing of various pharmaceutical products in China and internationally. The company offers Chinese medicine granules, finished pharmaceutical products, raw materials and excipients, medical devices, healthcare services, and smart supply chain for pharmaceutical and medical devices. It provides its products in the areas of severe disease, cardiovascular, cerebrovascular system, respiratory system, neurodegenerative, and anti-tumor. The company was founded in 1996 and is based in Tianjin, China.

www.chasesun.cn

5,910

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: 300026.SZ

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

300026.SZ
12.97%
SSE Composite Index
3.82%

1-Year Return

300026.SZ
32.43%
SSE Composite Index
5.40%

3-Year Return

300026.SZ
5.74%
SSE Composite Index
11.10%

5-Year Return

300026.SZ
11.03%
SSE Composite Index
1.13%

Compare To: 300026.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300026.SZ

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    11.09B

  • Enterprise Value

    11.06B

  • Trailing P/E

    28.38

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.86

  • Price/Book (mrq)

    1.26

  • Enterprise Value/Revenue

    1.87

  • Enterprise Value/EBITDA

    20.89

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.58%

  • Return on Assets (ttm)

    1.96%

  • Return on Equity (ttm)

    4.30%

  • Revenue (ttm)

    5.91B

  • Net Income Avi to Common (ttm)

    389.3M

  • Diluted EPS (ttm)

    0.1300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.62B

  • Total Debt/Equity (mrq)

    17.81%

  • Levered Free Cash Flow (ttm)

    502.89M

Research Analysis: 300026.SZ

Analyst Price Targets

 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Company Insights: 300026.SZ

People Also Watch